Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (NCT05098132)
A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.
Who can join: Review the eligibility criteria below.
Location: University of Arizona Cancer Center — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (47 Sites)
Showing the first 25 of 47 sites.
- University of Arizona Cancer Center — Tucson, Arizona
- Beverly Hills Cancer Center — Beverly Hills, California
- Providence Medical Foundation — Fullerton, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Cedars Sinai — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
- Yale New Haven Hospital, Yale Cancer Center — New Haven, Connecticut
- Georgetown University — Washington D.C., District of Columbia
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- University of Chicago — Chicago, Illinois
- University of Maryland — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- HealthPartners Cancer Center at Regions Hospital — Saint Paul, Minnesota
- Northwell Health — Lake Success, New York
- NYU Langone Health — New York, New York
- Columbia University Irving Medical Center — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Duke Cancer Center — Durham, North Carolina
- University Hospitals Cleveland — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
- Providence Cancer Institute — Portland, Oregon
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (650) 606-6319
Email: STK-012-101.contact@synthekine.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.